Citius Pharmaceuticals, Inc. (CTXR)

Citius Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Net Income	-42.07	-39.43	-32.54	-33.64	-23.05	-17.55
Depreciation & Amortization	0.21	0.21	0.19	0.18	0.16	0.15
Stock-Based Compensation	-1.25	12.12	6.72	4.28	1.52	1.33
Other Adjustments	0.94	0.58	0.58	0.58	-0.17	-
Changes in Inventories	-11.07	-2.13	-	-	-	-
Changes in Accounts Payable	8.43	2	1.76	-0.11	-0.58	-0.86
Changes in Accrued Expenses	9.98	-0.39	-0.53	0.64	0.62	0.19
Changes in Other Operating Activities	2.42	-1.16	-5.23	-0.29	-2.76	-0.2
Operating Cash Flow	-20.58	-28.2	-29.06	-28.36	-24.25	-16.93
Capital Expenditures	-	-	-	-	-0.01	-0
Purchases of Intangible Assets	-	-5	-	-	-40	-
Investing Cash Flow	-	-5	-	-	-40.01	-0
Long-Term Debt Issued	-	-	-	-	-	0.16
Long-Term Debt Repaid	-	-	-	-	-0.17	-
Net Long-Term Debt Issued (Repaid)	-	-	-	-	-0.17	0.16
Issuance of Common Stock	-	13.8	13.83	-	120.64	22.73
Net Common Stock Issued (Repurchased)	-	13.8	13.83	-	120.64	22.73
Other Financing Activities	-	-3.83	-	-	-	-
Financing Cash Flow	13.76	9.97	13.83	-	120.47	22.9
Net Cash Flow	-11.82	-23.23	-15.23	-28.36	56.21	5.97
Beginning Cash & Cash Equivalents	17.91	26.48	41.71	70.07	13.86	7.89
Ending Cash & Cash Equivalents	6.09	3.25	26.48	41.71	70.07	13.86
Free Cash Flow	-20.58	-28.2	-29.06	-28.36	-24.26	-16.93
Free Cash Flow Per Share	-2.40	-4.19	-4.80	-4.85	-5.58	-10.81
Levered Free Cash Flow	-31.03	-41.66	-37.51	-33.22	-27.24	-18.1
Unlevered Free Cash Flow	-32.11	-44.09	-41.21	-33.48	-26.09	-18.43

Updated Dec 23, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q